Year: 2014
Type: review
Abstract: Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,237
Funders: Eli Lilly and Company, Wellcome Trust, National Brain Appeal, Motor Neurone Disease Research Australia, National Institute for Health and Care Research, Centre of Excellence in Cognition and its Disorders, Australian Research Council, Avid Radiopharmaceuticals, Medical Research Council, Australian Research Council, National Health and Medical Research Council
OpenAlex ID: W2047462352
